loading page

FLAG with Bortezomib in Childhood Relapsed Refractory Leukaemia- A Single Centre Experience
  • +4
  • Sreedhar Jayakrishnan Cherulil,
  • KESAVAN MELARCODE RAMANAN,
  • Gangadharan KV,
  • Sreelesh KP,
  • Arun Chandrashekaran,
  • Sudeep Vaniath,
  • Karthika KV
Sreedhar Jayakrishnan Cherulil
Malabar Institute of Medical Sciences Ltd

Corresponding Author:[email protected]

Author Profile
KESAVAN MELARCODE RAMANAN
Malabar Institute of Medical Sciences Ltd
Author Profile
Gangadharan KV
Malabar Institute of Medical Sciences Ltd
Author Profile
Sreelesh KP
Malabar Institute of Medical Sciences Ltd
Author Profile
Arun Chandrashekaran
Malabar Institute of Medical Sciences Ltd
Author Profile
Sudeep Vaniath
Malabar Institute of Medical Sciences Ltd
Author Profile
Karthika KV
Malabar Institute of Medical Sciences Ltd
Author Profile

Abstract

Relapsed refractory leukaemia represents a difficult to treat population of patients. The balance between perceived benefit and potential side effects along with the significant financial burden of managing multidrug resistant sepsis are factors which determine the choice of salvage regimen. Here we present our experience with the combination of Fludrabine, Cytarabine, GCSF with Bortezomib. The morphological complete response rate was 58.% with 50% of the patients achieving complete remission. With only three patients requiring ICU admission during the period of care. 66.6% of the patients went on to undergo successful hematopoietic stem cell transplantation. Thus, proving to be a possible, safer alternative to other salvage regimens